

# The effects of structured follow-up from primary care for patients during their cancer journey. A randomized controlled trial.

No registrations found.

<b>Ethical review</b>	Positive opinion
<b>Status</b>	Recruiting
<b>Health condition type</b>	-
<b>Study type</b>	Interventional

## Summary

### ID

NL-OMON28691

### Source

NTR

### Brief title

GRIP study

### Health condition

Cancer

## Sponsors and support

**Primary sponsor:** Universitair Medisch Centrum Utrecht (UMCU)

**Source(s) of monetary or material Support:** Danone Ecosystem Fund

## Intervention

## Outcome measures

### Primary outcome

1) Patient satisfaction with care

2) Health care utilisation

### **Secondary outcome**

1) Health related quality of life

2) Employment

3) Effect on patient empowerment

4) Shared decision making

5) Mental health

## **Study description**

### **Background summary**

Health care professionals and patients advocate transfer of care and follow-up from secondary to primary care in the Netherlands, due to the increase in the number of chronic cancer patients, cancer incidence and improving outcomes of cancer therapy and expanding possibilities for personalized cancer care. However, the effectiveness of structured patient follow-up from primary care during the cancer journey has not been studied yet. Therefore, the GRIP study, a multicenter randomized controlled two-arm trial, evaluates the effects of structured follow-up care from diagnosis, for cancer patients provided from primary care on healthcare utilization and patient satisfaction with care.

Country of recruitment: The Netherlands

### **Study objective**

Structured follow-up from primary care will effect patients' satisfaction with care and health care utilisation.

### **Study design**

1) Time Out consultation with the GP after diagnosis and before final treatment decision.

2) Contact with HON during and after treatment, at least 3 contacts.

3) Questionnaires will be send at the moment of consensus for participation (T0), two weeks after inclusion (T1), three months after inclusion (T2), six months after inclusion (T3), nine months after inclusion (T4) and twelve months after inclusion (T5).

Timing of T3-T5 depends on duration of therapy. T5 will always be send 3 months after end of therapy.

### **Intervention**

- 1) Time out consultation with general practitioner
- 2) Home visits by Homecare Oncology Nurse

## **Contacts**

### **Public**

University Medical Center Utrecht, Str. 6.131 - Julius Center

C.W. Helsper  
PO Box 85500

Utrecht 3508 GA  
The Netherlands  
T: 0614212460

### **Scientific**

University Medical Center Utrecht, Str. 6.131 - Julius Center

C.W. Helsper  
PO Box 85500

Utrecht 3508 GA  
The Netherlands  
T: 0614212460

## **Eligibility criteria**

### **Inclusion criteria**

- 1) Newly diagnosed with the following types of cancer: breast cancer, colorectal cancer, gynaecologic cancer, lung cancer or melanoma.
- 2) Cancer therapy is to be initiated with curative intent.
- 3) Patients' general practitioner participates in the GRIP study.
- 4) Patient is 18 years old or older.

5) Inclusion within two weeks after diagnosis.

## Exclusion criteria

1) Major psychiatric disease and personality disorders.

2) Unable to fill in questionnaires.

## Study design

### Design

Study type:	Interventional
Intervention model:	Parallel
Allocation:	Randomized controlled trial
Masking:	Open (masking not used)
Control:	Active

### Recruitment

NL	
Recruitment status:	Recruiting
Start date (anticipated):	01-03-2015
Enrollment:	150
Type:	Anticipated

## Ethics review

Positive opinion	
Date:	21-06-2016
Application type:	First submission

## Study registrations

## Followed up by the following (possibly more current) registration

No registrations found.

## Other (possibly less up-to-date) registrations in this register

No registrations found.

## In other registers

Register	ID
NTR-new	NL5672
NTR-old	NTR5909
Other	METC : 15-075/C

## Study results